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ABSTRACT 
Sorafenib targets the Raf/mitogen activated protein kinase, VEGF and PDGF pathways and 
prolongs survival patients in advanced hepatocellular carcinoma (HCC).  Everolimus inhibits 
the mammalian target of rapamycin, a kinase overactive in HCC. To investigate whether the 
antitumor effects of these agents are additive, we compared a combined and sequential 
treatment regimen of everolimus and sorafenib with monotherapy.  After hepatic implantation 
of Morris Hepatoma cells, rats were randomly allocated to everolimus (5mg/kg, 2x/week), 
sorafenib (7.5mg/kg/day), combined everolimus and sorafenib, sequential sorafenib (2 weeks) 
then everolimus (3 weeks), or control groups.  Magnetic resonance imaging quantified tumor 
volumes.  Erk1/2, 4E-BP1 and their phosphorylated forms were quantified by 
immunoblotting.  Angiogenesis was assessed in vitro by aortic ring and tube formation assays, 
and in vivo with Vegf-a mRNA and vascular casts.  After 35 days, tumor volumes were 
reduced by 60%, 85% and 55%, relative to controls, in everolimus, the combination and 
sequential groups, respectively (p<0.01).  Survival was longest in the combination group 
(p<0.001).  Phosphorylation of 4E-BP1 and Erk1/2 decreased after everolimus and sorafenib, 
respectively.  Angiogenesis decreased after all treatments (p<0.05), although sorafenib 
increased Vegf-a mRNA in liver tumors.  Vessel sprouting was abundant in control tumors, 
lower after sorafenib and absent after the combination.  Intussusceptive angiogenic 
transluminal pillars failed to coalesce after the combination.  Combined treatment with 
everolimus and sorafenib exerts a stronger antitumoral effect on MH tumors than 
monotherapy.  Everolimus retains antitumoral properties when administered sequentially after 
sorafenib.  This supports the clinical use of everolimus in HCC, both in combination with 
sorafenib or after sorafenib.  
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INTRODUCTION 
Sorafenib is the only drug for which randomized control trials have shown an improved 
survival in advanced hepatocellular carcinoma (HCC) [1], [2], and is the only systemic 
targeted therapy approved for clinical use in many countries.  Sorafenib inhibits the kinase 
activity of Raf, an enzyme operative within the mitogen-activated protein kinase (MAPK) 
signaling pathway and inhibits the vascular endothelial growth factor receptors (VEGFR) and 
platelet-derived growth factor receptor-ȕ PDGF-ȕ  In many cases of HCC, Ras kinase is 
over-expressed or mutated and the Raf/MAPK pathway is activated [3].  As a result of the 
inhibition of these target molecules, sorafenib decreases tumor microvessel density and exerts 
an anti-proliferative effect on tumor cells [4].  Despite these actions, sorafenib only extends 
the life expectancy of patients with HCC by a few months, suggesting that other signaling 
pathways remain active. 
 
Additional pathways implicated in tumorigenesis include those signaling through  
PI(3)K/AktP725:17ȕ-catenin, insulin-like growth factor, hepatocyte growth factor/c-
MET and growth factor-regulated angiogenic signaling (VEGF, PDGF, EGF) [5].  In this 
study we focused on the PI(3)K/Akt/mTOR signaling cascade. The mammalian target of 
rapamycin (mTOR), which is the downstream target of the serine/threonine kinase Akt, 
increases protein synthesis and cell proliferation in response to growth factors.  
Pharmacological inhibition of mTOR by rapamycin and its analogues arrests the cell cycle by 
abrogating the PI(3)K/Akt-mediated proliferative signals.  Moreover, mTOR inhibitors reduce 
the expression of VEGF, which is associated with tumor angiogenesis [6]. We reported 
previously that inhibition of mTOR significantly slows tumor growth, impairs the tumor 
angiogenesis that occurs by sprouting, and improves survival in an experimental HCC model 
[6].  Everolimus, a rapamycin analogue, is the only mTOR inhibitor currently under 
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investigation in clinical HCC trials, either as monotherapy or combined with other therapeutic 
options, such as bevacizumab, sorafenib, and transarterial chemoembolization with 
doxorubicin.  Since the activities of mTOR inhibitors and sorafenib occur at separate stages 
along two signaling pathways, their combination could be complementary and provide more 
effective suppression of HCC.  Although the combination of sorafenib and rapamycin has 
shown synergistic inhibition of HCC xenografts [7], important information is lacking with 
respect to the mechanisms of this synergism and the specific effects of the drug combination 
on angiogenic processes.  Additional uncertainties relate to the most effective means of 
administering the drug combination and whether patients who have been unresponsive or 
intolerant to sorafenib could subsequently benefit from an mTOR inhibitor.   
 
We asked whether the anti-proliferative and anti-angiogenic properties of everolimus and 
sorafenib in liver tumors are additive when administered in combination, whether their 
concomitant use improves survival, and whether administration of everolimus sequentially 
after sorafenib is beneficial.  We chose an orthotopic syngeneic rat model of HCC and 
examined the effects of everolimus and sorafenib on tumor vasculature and different cell 
types.  Our results provide a rationale for combining everolimus with sorafenib in HCC.  
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MATERIAL AND METHODS 
Animals and surgical procedures 
Animal experiments were approved by the Local Animal Use Committee.  The livers of male 
ACI rats (Harlan, Indianapolis, IN), 10-12 weeks old, were surgically implanted with tumors 
derived from Morris Hepatoma MH-3924A  cells as previously described [6], [8].   
 
Animal treatment protocol 
On day 6 post tumor implantation, the rats were randomized to a group receiving either 
everolimus (5mg/kg 2x/week; Novartis, Basel, Switzerland; structural formula in 
Supplementary Figure 1A), sorafenib (7.5mg/kg/day; Bayer HealthCare Pharmaceuticals 
Montville, NJ; structural formula in Supplementary Figure 1B), the combination of 
everolimus and sorafenib, or the successive treatment of sorafenib for 2 weeks followed by 
everolimus for 3 weeks, or to a control group.  Drugs and vehicle were administered by 
gavage.  Rats were euthanized on day 42 after tumor implantation.  In a second series of 
experiments designed to measure survival, animals were treated until the appearance of signs 
of wasting or suffering that indicated distress (deterioration of the general state of the animals, 
loss of weight greater than 20%, severe piloerection, harderian gland secretion, abnormal 
posture and behaviour), at which point they were euthanized.  The investigators were blinded 
to treatment allocation.  
 
MR Imaging 
Liver MR imaging with a commercial 3.0 Tesla system (TIM TRIO, Siemens, Erlangen, 
Germany) of tumors was first performed on day 11 after tumor implantation and weekly 
thereafter.  All animals received food and water ad libitum. Animals were anesthetized and 
placed prone and head first in an eight-channel-wrist coil. After visualization of the liver, a 
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volume adapted high resolution T2 weighted Turbo Spin Echo sequence with fat suppression 
was acquired in the coronal plane and repeated in the axial acquisition direction (repetition 
time/echo time max/66; voxel size 0.3 x 0.3 x 2 mm3, matrix 384, turbo factor 14, acquisition 
time 4.48 min). Data were analyzed on a post-processing workstation (Leonardo, Siemens, 
Erlangen, Germany).  The largest diameter of the tumor was measured in three planes 
perpendicular to each other.  The volume of tumor ellipsoids in mm3 ZDVFDOFXODWHGDVÂʌ
· r1 · r2 · r3 (with r1, r2 and r3 representing perpendicular radii of the lesion). 
  
Immunohistochemistry 
Tumor necrosis was assessed by staining tumor sections with Giemsa and by quantifying the 
necrotic area using the software Metamorph. Tumoral apoptosis was measured in paraffin-
embedded sections by cleaved-caspase 3 immunostaining (Cell Signaling, Beverly, MA).   
Tumoral hypoxia was measured in paraffin-embedded sections by HIF-Į  LPPXQRVWDLQLng 
(Abcam, Cambridge, UK) with classification as follows: 0, no HIF positive tumoral cells; 1, 
<10% HIF positive tumoral cells; 2, 10-20% HIF positive tumoral cells; 3, 20-50% HIF 
positive tumoral cells; 4, >50% HIF positive tumoral cells. Tumoral invasiveness was 
assessed in paraffin-embedded sections by immunohistochemical staining for E-Cadherin 
(Abcam). 
 
Real time quantitative PCR 
Total RNA was extracted from liver by means of an RNeasy Mini Kit (Qiagen, 
Hombrechtikon, Switzerland) then was reverse-transcribed using SuperscriptIII Reverse 
Transcriptase (Invitrogen, Basel, Switzerland) and a random hexamer mix.  The probe and 
primers for Vegf-a were obtained from TaqMan® Gene Expression Assays (Applied 
Biosystem, Rotkreuz, Switzerland) and quantitative PCR was performed using an ABI 
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PRISM 7500 Sequence Detection System and the TaqMan universal PCR Master Mix, 
according to standard protocols. The Ct for each gene were standardized against ribosomal 
51$VWRREWDLQWKHǻCt YDOXHV7KHǻǻCt YDOXHVZHUHFDOFXODWHGE\VXEVWUDFWLQJWKHǻCt 
YDOXHVRIDQLPDOVWUHDWHGZLWKYHKLFOHIURPǻCt values of rats treated with the different drugs.  
Relative fold increases or decreases were calculated using the formula 2-ǻǻCt. All reactions 
were performed in triplicate. 
 
Vascular casting 
As previously described [9], the liver vasculature was perfused with a freshly prepared 
solution of Mercox® (Vilene Company, Japan) containing 0.1 ml accelerator per 5 ml resin. 
One hour after perfusion, the tumors were excised and macerated in 15% potassium 
hydroxide.  After 3 to 4 weeks, the casts were washed and dehydrated in ethanol and 
desiccated under vacuum.  Samples were layered with gold to a thickness of 10 nm and 
examined in a Philips XL 30 FEG scanning electron microscope. 
 
Cells and culture conditions    
MH-3924A (Morris Hepatoma, MH) cells were obtained from DKFZ (Heidelberg, Germany) 
and not further authenticated.  Isolated rat aortic endothelial cells (EC) were cultured as 
described by Semela et al. [6] and characterized by immunofluorescence with antibodies to 
vonWillebrand Factor/Factor VIII and CD31 (P-CAM).  Human hepatic sinusoidal 
endothelial cells (HHSEC) (ScienCell Research Laboratories, San Diego, CA) were 
characterized by the supplier by immunofluorescence with antibodies to vonWillebrand 
Factor/Factor VIII and CD31 (P-CAM) 
  
3H-Thymidine incorporation assay 
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MH and rat aortic endothelial cells were serum-starved overnight, then incubated with various 
concentrations of everolimus and sorafenib for 24 hours.  3H-Thymidine (0.2 μCi/ml, 
Amersham Biosciences, Otelfingen, Switzerland) was added in the presence of drugs and the 
incubation continued for 24 hours.  Cell proliferation was measured by counting the 
incorporation of 3H-Thymidine.  Experiments were repeated 3 times in triplicate. 
 
Rat aortic ring assay 
Aortic rings were prepared as previously described [6].  Everolimus and/or sorafenib were 
added 24h after preparation and rings were incubated for 5 days.  For sequential drug 
treatment, rings were incubated with sorafenib for two days, the medium was changed and 
everolimus was added.  At day 5, the rings were fixed and stained according to a Diff-Quick 
solution II protocol (Diff-Quick Stain Set; Baxter-Dade AG, Switzerland). Vascular 
outgrowth was quantified by counting the sprouts. 
 
Tube formation assay 
HHSEC (4x104) were incubated in 24-well plates coated with Matrigel in the presence or 
absence of everolimus and/or sorafenib. After 72 hours, the area covered with vascular tubes 
was quantified using the Metamorph software (Molecular Devices, Sunnyvale, CA). 
Experiments were performed 3 times in duplicate. 
 
Immunoblot analysis 
Liver tissue was homogenized in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS and 50 mM Tris-HCl pH 7.4) containing protease and phosphatase 
inhibitors (Roche, Rotkreuz, Switzerland).  Protein concentration was assayed according to 
Lowry [10].  Equal amount of proteins were separated by SDS-PAGE and transferred to 
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nitrocellulose membranes, blocked for 1 hour with 5% nonfat milk, then incubated overnight 
at 4°C with cleaved-Caspase 3, phospho-Erk1/2, phospho-4E-BP1, phospho-Elk1 and 
phospho-Akt (Ser473) antibodies (Cell Signaling, Beverly, MA). After washing, the 
membranes were incubated with peroxidase-conjugated secondary antibody (Pierce, 
Lausanne, Switzerland) and signals were revealed using an enhanced chemiluminescence 
detection system (Perkin Elmer, Schwerzenbach, Switzerland) and a Fujifilm LAS.100 CCD 
camera coupled to a computer using the software AIDA 2.1 (Raytest, Urdorf, Switzerland). 
Membranes were stripped and reincubated with antibodies against total Erk1/2, 4E-BP1, Elk1 
and Akt (Cell Signaling). Membranes were stripped again before incubation with anti-ȕ-actin 
antibody (Sigma-Aldrich Chemie GmbH, Munich, Germany) and protein was normalized for 
actin expression. 
 
Statistical analysis 
Data points represent the mean values ± SD. Data were compared by applying the 
nonparametric Mann-Whitney U test.  A p value <0.05 was considered statistically 
significant. 
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RESULTS 
Effect of everolimus ± sorafenib on tumor progression.  MR imaging 35 days after tumor 
implantation showed smaller tumors in the treated livers than the untreated livers (Figure 1A).  
Tumor volumes were significantly smaller in the combined sorafenib + everolimus group than 
all other groups (p<0.01 vs. control; p<0.05 vs. sorafenib; p<0.01 vs. everolimus and vs. 
sequential everolimus-sorafenib) (Figure 1B).  The sequential sorafenib-everolimus treatment 
and everolimus monotherapy were equally effective.  Monotherapy with sorafenib was the 
least effective.  At harvest, tumor sizes were 166±53 mm3 after combined sorafenib and 
everolimus, 421±84 mm
3
 after everolimus, 511±183 mm
3
 after sorafenib for 2 weeks then 
everolimus for 3 weeks, 805±317 mm
3 
after sorafenib, and 1139±238 mm
3 
for the untreated 
group. The median survival was longest for the combined everolimus-sorafenib group (70 
days, p<0.001 vs. control and sorafenib groups), shorter for sorafenib monotherapy (63.5 
days) and shortest for the controls (57 days) (Figure 1C).  Rats tolerated the treatments for the 
duration of the study (42 days).  The body weights ranged from 234 ±12 g for the 
combination group to 273 ±14 g for the control group.  However, the longer treatment 
imposed by the design of the survival study was associated with tooth fractures in the rats 
treated with sorafenib.  Tooth fractures were noted after 8 weeks, and could have caused a 
secondary weight loss.  Although the extent of tumor necrosis was not significantly affected 
by any of the treatments, a higher trend of necrosis was noted in the combined everolimus-
sorafenib group (Figure 2A and Supplementary Figure 2A).  Treatment with everolimus or 
sorafenib was associated with apoptosis, more so after sorfanib, as assessed by immunoblots 
and immunohistochemical detection of cleaved caspase 3 (Figure 2B and 2C).  The degree of 
hypoxia in tumors was estimated by HIF-Į immunostaining.  The number of HIF-Į positive 
tumor cells was higher in the tumors treated with everolimus, sorafenib and the combination 
than in the control group (p<0.01).  The number of HIF-Į SRVLWLYH FHOOV ZDV also 
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significantly greater in the sequential sorafenib-everolimus treated tumors than in controls but 
achieved a lower statistical score (p<0.05) (Figure 2D and Supplementary Figure 2B). 
 
Antiproliferative and anti-angiogenic effects of everolimus-sorafenib in vitro.  Relative to 
control conditions, the proliferation of rat endothelial cells decreased by 40% in the presence 
of everolimus (20-200 nM).  The effect was not dose dependent and was not potentiated by 
the addition of sorafenib (Figure 3A).  Sorafenib alone from 100 nM to 10 ȝ0KDGQRHIIHFW
In contrast, the proliferation of hepatoma MH cells was insensitive to everolimus alone (20-
2000 nM).   Sorafenib alone was anti-proliferative only at the highest concentration (ȝ0).  
The addition of everolimus lowered the minimal effective concentration of sorafenib to 5 ȝ0
(Figure 3B).  
 
The effect of sorafenib and everolimus on angiogenesis in vitro was measured in two ways.  
In the aortic ring assay, everolimus 200 nM and sorafenib 100 nM alone significantly 
decreased sprouting from aortic rings by 60% (Figure 4A). The combination of drugs, either 
in a concomitant or sequential regimen, decreased sprouting even further (Figure 4A).  In fact, 
vessel sprouting was most inhibited by the sequential sorafenib-everolimus treatment 
protocol.  The tube formation assay measures the ability of endothelial cells to form a linear 
structure and in contrast to the ring aortic assay, operates without the confounding influences 
of pericytes and fibroblasts.  Endothelial tube formation was significantly impaired by 
everolimus both in monotherapy and in combination (Figure 4B).  Sorafenib had no effect in 
this assay.    
 
Effect of combined everolimus ± sorafenib on tumors in vivo.  Compared to controls, the 
mRNA levels of Vegf-a were increased by 86% after sorafenib (p<0.05) although this effect 
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was blunted to 49% upon addition of everolimus (Figure 5A).  Everolimus alone did not 
produce a significant effect in Vegf-a mRNA.  Everolimus alone decreased phosphorylation of 
4E-BP1 in total tumor tissue, whereas the addition of sorafenib tended to blunt this effect 
(Figures 5B and Supplementary Figure 3A).  Sorafenib alone decreased the phosphorylation 
of Erk1/2 in tumors but this effect was lost in combination with everolimus (Figures 5B and 
Supplementary Figure 3B).  Sorafenib alone also decreased the phosphorylation of the Erk1/2 
target, Elk1, in tumors (Supplementary Figure 3C and 3D).  The phosphorylation of Akt on 
Ser473, which is a site phosphorylated by the complex mTORC2, was increased in the tumors 
treated with sorafenib and everolimus (Figure 5C and Supplementary Figure 3E).   
 
Vascular casts revealed abundant sprouting in tumors of the control group, whereas sprouting 
was reduced in sorafenib treated tumors and absent in tumors treated with everolimus and 
sorafenib (Figure 6A).  Vessels were pierced by pillars in the sorafenib treated tumors as a 
sign of non-sprouting intussusceptive angiogenesis.  In the combination group, pillars were 
frequent but remained small and were positioned irregularly.  Histological analysis of the 
periphery of the tumor and application of a technique of digital quantification demonstrated 
that in the combination group, an invasive front intercalated extensively into the surrounding 
tissue (Figure 6B and Supplementary Figure 4A).  In contrast, the periphery of the tumors in 
the control group was regular and limited by a capsule.  The tumor periphery was examined 
by immunohistochemical staining for expression of E-cadherin.  In the tumors cells, E-
cadherin was prominent and cytoplasmic regardless of the treatment group.  In adjacent non-
tumoral hepatocytes at the interface, a peripheral membrane staining of E-cadherin was noted 
but only in the control group.  This feature was not seen in the hepatocytes adjacent to the 
invading tumor cells in the everolimus+sorafenib group (Supplementary Figure 4B). Despite 
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the invasive characteristics of the limiting edges of the treated tumors, histological analyses of 
the lungs of animals from all groups indicated no distant metastases.   
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DISCUSSION 
We previously reported that inhibition of the mTOR pathway, which is activated in many 
cases of HCC [11], [12], [13], decreases VEGF levels, impairs tumor angiogenesis, and 
results in smaller tumors and longer survival in a rat MH-3924A model of HCC [6].  We now 
show the benefits of combining an mTOR inhibitor with sorafenib, an inhibitor of B-Raf and 
Raf-1 kinases, as well as VEGF and PDGF receptor   Our findings show that combined 
everolimus and sorafenib is a more potent anti-tumor regimen than either agent alone, exerts a 
stronger anti-angiogenic effect than either agent alone and improves survival in this HCC 
model.  Everolimus also retains its antitumoral potency in vivo when administered 
sequentially after sorafenib, a finding that carries important clinical implications.  Our 
positive results contrast with those of Newell et al., who found no difference in tumor growth 
with this combination [14].  This disparity is perhaps explained by our propitious choice of an 
orthotopic syngeneic model, which is a closer representation of HCC than the xenograft 
model chosen by previous investigators [14], [7] , [15] 
 
HCC is a hypervascular tumor, relying on angiogenesis for growth [16].  Focal hypoxia is a 
potent angiogenic stimulus and both everolimus and sorafenib treatment regimens exerted 
their antitumoral effects within a local environment that was subject to such stimuli, as shown 
by the increased expression of HIF-1ĮLQDOOWUHDWHGWXPRUV)LJure 2D).  The upregulation of 
Vegf-a mRNA in the tumor by sorafenib, an effect also reported with other receptor tyrosine 
kinase inhibitors such as vatalanib [17] and sunitinib [18], can be attributed to a feedback 
response to the suppressed VEGF receptor signaling [19].  Despite this, hypoxia-driven 
neovascularisation was not seen in the treated liver tumors.  Rather, everolimus and sorafenib 
impaired angiogenesis and altered the structure of the tumor vascular architecture (Figure 
6A).  In keeping with our previous findings, where inhibition of mTOR with sirolimus 
15
ht
tp
://
do
c.
re
ro
.c
h
effected a switch in tumor angiogenesis from sprouting to intussusception [6],  the 
combination of everolimus/sorafenib promoted an increase in the number of vascular pillars 
but these pillars remained small, which suggests an inability to fuse, and consequently an 
impairment of the process of intussusception as a means of tumor vascularization.  We ascribe 
the superior ability of the everolimus and sorafenib combination to slow tumor growth to this 
impaired tumor angiogenesis and vascularization.  
 
 
 
The innate resistance of the MH-3924A cells to the anti-proliferative actions of mTOR 
inhibition and the low sensitivity to Raf/ERK blockade in vitro (Figure 3B) did not preclude a 
response to everolimus and sorafenib when these cells were implanted as solid tumors in vivo.  
Other investigators have reported similar anti-tumoral responses when insensitive cell lines 
were seeded in vivo [20], [21].  The everolimus mediated decrease in proliferation and 
migration of endothelial cells in vitro and impairment of vessel sprouting point to 
antiangiogenesis as the means by which the resistant tumors became sensitized to mTOR 
inhibition in vivo.  Lane et  al. postulated that the anti-antiogenic effects of everolimus were 
due to the combination of a reduced VEGF production in tumor cells and direct action on 
mTOR signalling in non-tumor pericytes and endothelial cells [20].  We have previously 
reported that another mTOR inhibitor, sirolimus, did decrease VEGF-a in MH-3924A derived 
tumors under different experimental circumstances [6].  A similar reduction was not detected 
with everolimus, although the sorafenib-induced increase in VEGF-a mRNA tended to be less 
acute in the presence of everolimus (Figure 5A).  Our findings appear more consistent with 
inhibition of mTOR signalling in endothelial cells (Figures 3A, 4). The basis for the resistance 
of MH-3924A cells to everolimus has not been investigated.  The presence of an oncogenic 
mutation in PI-3-NLQDVH FDWDO\WLF Į VXEXQLW DQG 37(1 ORVV RI IXQFWLRQ KDV been linked to 
mTOR inhibitor sensitivity [22].  Conversely, selected K-Ras mutations have been linked to 
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mTOR inhibitor insensitivity, as has overexpression of the myc oncogene [23].  The MH-
3924A cells likely overexpress K-Ras since gene amplification was detected in several Morris 
Hepatoma cell lines [24] but a more extensive genotyping is required to fully explain the 
response to mTOR signalling inhibition.  Genotyping may also explain the basis for the low 
sensitivity of MH-3924A cells to sorafenib (Figure 3B).  Tumor cell lines containing an 
activating receptor tyrosine kinase mutation are more sensitive to sorafenib whereas cell lines 
in which multiple signalling pathways drive growth are less sensitive [25].  The growth-
inhibitory response of MH-3924A tumors to sorafenib alone was poor (Figure 1B) despite a 
50% reduction in ERK phosphorylation (Figures 5B and S3), therefore multiple signalling 
pathways are likely important for proliferation of MH-3924A cells.  Sorafenib can also exert 
anti-tumor actions independent from the MEK/ERK pathway.  Sorafenib is apopotic in tumor 
tissue (Figures 2B and 2C), an effect likely explained by the reduced phosphorylation of the 
initiation factor eIF4E and downregulation of the antiapoptotic protein Mcl-1 [25].  Sorafenib 
blocks the VEGFR-2 receptor, an effect which could be linked to anti-angiogenesis through 
decreased endothelial cell survival.  Endothelial cell survival is assured through anti-apoptotic 
signalling, which normally occurs through Akt/PBK via the PI3 kinase-dependent pathway 
and up-regulation of anti-apoptotic protein signalling [26]. In support of this, sorafenib did 
decrease the phosphorylation of AKT in endothelial cells in vitro (data not shown).   
 
The molecular mechanism by which everolimus and sorafenib combine to exert effective anti-
tumor activity in MH-3924A derived tumors has been partly elucidated in our studies.  The 
combination therapy did increase the pAkt Ser473/Akt ratio in our tumor model (Figures 5C 
and S3), which was likely due to the mTOR complex 2-dependent phosphorylation of Akt in 
tumoral cells.  However, a higher AKT phosphorylation is not necessarily incompatible with a 
reduction in tumor growth [27], [28].  In fact, induction of p-AKT secondary to mTOR 
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inhibition was shown to be independent of the anti-proliferation cellular response to 
everolimus and modulation of AKT phosphorylation alone does not predict effects on 
downstream signalling [28].  Therefore, the anti-tumoral benefit of the combined treatment in 
our tumor model depends on pathways unrelated to the tumoral AKT signalling. The 
combination of everolimus and sorafenib also annulled the hypophosphorylation of 4E-BP1 
elicited by everolimus alone in tumor tissue (Figure S3).  However, the phosphorylation of the 
ribosomal protein S6 was completely inhibited in tumors treated with both everolimus and the 
combination (data not shown), which confirms the pharmacological inhibition of the mTOR 
complex 1.  Since the MH-3924A cell line is insensitive to everolimus, and inhibition of S6 
kinase and hypophosphorylated 4E-BP1 has been demonstrated in cell lines that were both 
sensitive and resistant to everolimus [28], we conclude that the ratio p4E-BP1/4E-BP1 in total 
tumoral tissue is not an adequate pharmacodynamic marker for the anti-tumoral effects of 
combined everolimus and sorafenib.  The addition of everolimus to sorafenib annulled the 
effect of sorafenib on the phosphorylation of Erk1/2 and downstream pElk1 (Figure S3).  One 
explanation is that Erk1/2 may be phosphorylated by a kinase other than Raf.  A second 
explanation is that the phosphorylation of Erk1/2 could be regulated by cross talk between 
PI3K/Akt and MAPK signaling due to a feedback loop affecting the S6K-PI3K-Ras pathway 
[29].  The increase in ERK phosphorylation observed after the combined everolimus and 
sorafenib is not incompatible with better anti-tumoral properties because of the likelihood that 
MEK/ERK-independent mechanisms are responsible for the reduced growth of MH-3924A 
tumors.  We argue that everolimus and sorafenib together reduced tumor growth in vivo more 
effectively than monotherapies primarily because of the combined effects of inhibition of 
mTOR signalling in endothelial cells and perhaps in non-tumor pericytes [20], and of 
sorafenib-induced tumor cell apoptosis and reduced anti-apoptotic signalling in endothelial 
cells and perhaps in other supportive cells of the vasculature.   
18
ht
tp
://
do
c.
re
ro
.c
h
 A comparison of the peripheral tumor regions revealed distinct histological differences 
between treatment and control groups.  The tumor front, which was linear and often 
encapsulated in the control group, appeared irregular and invasive after treatment, and 
prominently intermingled with the surrounding tissue to produce isolated islands of tumor 
tissue.  These features were particularly evident in the combination group.  Although this 
suggested a more invasive tumor phenotype [30], no distant metastases were detected in any 
of the animals at the time of harvesting.  We speculate that the treated tumors differed from 
the untreated tumors because the treated tumors have evolved in an anti-angiogenic 
environment and must rely on the blood supply at the peripheral edges to support growth.     
Whether the differences in staining pattern of E-cadherin at the tumor interface influence the 
pattern of invasiveness observed is not known at this point [31]. 
 
Despite a superior reduction in tumor growth, the effect of the everolimus-sorafenib 
combination on the median survival remained modest in comparison to the other treatment 
options.  Our survival study was designed with conditions wherein rats were euthanized when 
explicit endpoint criteria linked to distress had been reached.  Because the endpoint criteria 
would have precipitated termination of the study for the distressed animals, the effect of the 
combination everolimus-sorafenib on the median survival was modest.  We would expect a 
larger clinical effect on the median natural survival of patients.    
 
The sequential administration of everolimus after sorafenib may be clinically useful in certain 
circumstances.  In clinical trials, 40% of the HCC patients treated with sorafenib develop side 
effects severe enough to warrant discontinuation of the treatment.  Such patients deprived of 
targeted therapy are then exposed to a rebound effect, which has been shown experimentally, 
19
ht
tp
://
do
c.
re
ro
.c
h
although no mechanism was postulated [32].  This rebound effect could be provoked partly by 
an increased concentration of growth factors such as VEGF as we report here, which may fuel 
tumor growth if left unopposed.  Our results offer reassurance that patients can still benefit 
from an alternative systemic targeted therapy after sorafenib and that everolimus can still 
exert its antiangiogenic effects.  However, the extent of the clinical improvement that can be 
offered to patients remains to be verified.  One must also carefully consider whether the 
combination of an inhibitor of mTOR and sorafenib will be tolerated by patients with liver 
cirrhosis.   
 
In conclusion, our results present mechanistic insights into the treatment of HCC with 
everolimus either in combination with sorafenib or in subsequent treatment and provide the 
experimental basis for testing this combination in clinical trials. 
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FIGURE LEGENDS  
Fig. 1.  Effect of the combination of everolimus and sorafenib on tumor growth and 
survival of rats implanted with Morris Hepatoma tumor cells.   A. Representative 
magnetic resonance images (MRI) of the liver of untreated (vehicle) and treated rats. 
MRI images were generated 35 days after tumor cell implantation.  The tumors (arrows) are 
smaller in each treatment group than in the untreated liver.  B.  Tumor volume as a function 
of time in untreated and treated rats.  The volume of tumors was measured on MRI images 
taken weekly after tumor cell implantation.  On day 35, when compared to untreated tumors, 
the tumor volumes had decreased by 29% after sorafenib treatment, 55% after sequential 
sorafenib then everolimus, 50% after everolimus and 85% after combined treatment. (*, 
p<0.01 in comparison to control; +, p<0.01 in comparison to combination; #, p<0.05 in 
comparison to sorafenib; N=6 for control, everolimus and sequential treatments, N=5 for 
sorafenib treatment and N=4 combination treatment).  C.  Survival curve of rats implanted 
with MH tumor cells.  The median survival was 57 days in the control group, 63.5 days 
when treated with sorafenib and 70 days when treated with the combination sorafenib-
everolimus (*, p<0.001 vs vehicle, +, p<0.001 vs sorafenib; N=7 for vehicle treatment, N=6 
for sorafenib treatment and N=5 for combination treatment). 
 
Fig. 2. Effect of the combination of everolimus and sorafenib on tumor necrosis (A), 
tumor apoptosis (B and C) and tumor hypoxia (D).  A. Extent of necrosis, assessed by 
Giemsa staining, in tumors of rats implanted with Morris Hepatoma cells.  The 
percentage of necrotic area relative to the total area was quantified.  The necrotic area was 
similar in all groups although necrosis was slightly but not significantly increased in the 
combination group (N=6 for vehicle and sequential treatments, N=5 for everolimus and 
sorafenib treatments and N=4 for combination treatment).  B. and C. Apoptosis in tumoral 
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tissue assessed by the presence of cleaved-caspase 3.   Immunoblots (B) of cleaved caspase-
3 were compared in liver tumors from rats untreated (vehicle) and treated with everolimus and 
sorafenib, alone or in combination.  Two to three representative immunoblots from each 
treatment group are shown.  Actin was used as a loading control.  Immunostaining (C, 10x 
magnification) for cleaved caspse-3 in tumors representating untreated (vehicle) and treated 
groups.  Compared to the untreated group, the amount of cleaved-caspase 3 tended to increase 
in tumors of animals treated with everolimus, sorafenib, the combination of both drugs or 
with the sequential treatment.  D. Hypoxia of liver tumors assessed by HIF-Į
immunostaining (10x magnification).  Compared to the untreated group, the number of HIF-
Į SRVLWLYH FHOOV ZDV VLJQLILFDQWO\ LQFUHDVHG E\ HYHUROLPXV VRUDIHQLE WKH FRPELQDWLRQ RI
drugs and the sequential treatment. 
 
Fig. 3.   Effect of the combination of everolimus and sorafenib on rat aortic endothelial 
cell and Morris Hepatoma cell proliferation.  A. Cell proliferation was measured by 3H-
Thymidine incorporation into rat aortic endothelial cells.  Sorafenib did not affect 
proliferation of aortic endothelial cells.  Everolimus 20nM significantly decreased 
proliferation by 40%. There was no additive effect when sorafenib and everolimus were 
combined. (*, p<0.05 vs complete medium).   B. In Morris Hepatoma cells, sorafenib 1ȝ0
inhibited the proliferation, in contrast to everolimus.  The minimum effective concentration of 
VRUDIHQLEZDVORZHUHGWRȝ0XSRQWKHDGGLWLRQRIHYHUROLPXV([SHULPHQWVZHUHSHUIRUPHG
three times in triplicate; *, p<0.05 vs complete medium, #, p<0.0 YV VRUDIHQLE ȝ0 
SYVVRUDIHQLEȝ0DQGSYVHYHUROLPXVQ0VRUDIHQLEȝ0 
 
Fig. 4.  Effect of the combination of everolimus and sorafenib on angiogenesis in vitro. 
A.  Aortic rings isolated from ACI rats were incubated in medium on Matrigel with or without 
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everolimus 200nM and/or sorafenib 100nM.  After 5 days of incubation, rings were fixed, 
stained and photographed (left). Vascular outgrowth was quantified by counting all capillary 
sprouts from one ring and normalizing to vehicle (control) (right). Both everolimus and 
sorafenib alone significantly decreased vessel sprouting compared to the vehicle group. This 
effect was greater when the drugs were combined and further magnified when rings were 
incubated with sorafenib for 2 days then everolimus (N=6 for each experimental condition) 
(*, p<0.05 vs vehicle, +, p<0.05 vs sorafenib 100nM, then everolimus 200nM).   B. Human 
hepatic sinusoidal endothelial cells were incubated on Matrigel with or without everolimus 
20nM and/or sorafenib 100nM. After 72 hours of incubation, photomicrographs were 
recorded at random.  Areas covered by vascular tubes were digitally quantified using the 
software Metamorph. Everolimus significantly decreased capillary tube formation, compared 
to the vehicle group. Addition of sorafenib did not further increase this effect (*, p<0.05 vs 
vehicle. 
 
Fig. 5. Effect of everolimus and sorafenib treatment on gene expression of Vegf-a and on 
the phosphorylation of target proteins in tumoral tissue.   A. Tumoral mRNA expression 
of Vegf-a.  mRNA was extracted from liver tumors and the level of Vegf-a was measured by 
quantitative real-time PCR.  Compared to the vehicle (control) group, Vegf-a mRNA 
increased after sorafenib (*, p<0.05 vs vehicle).  Tumors treated with the combination of 
everolimus and sorafenib expressed higher mRNA levels of Vegf-a than everolimus alone ( +, 
p<0.05 vs everolimus). N=6 for sequential treatment, N=5 for vehicle and everolimus 
treatments, N=4 for sorafenib and combination treatment.   B. Effect of treatment on the 
expression and phosphorylation of 4E-BP1 and Erk1/2 in tumors.   Immunoblots of 
phosphorylated 4E-BP1 and Erk1/2, which are target proteins of everolimus and sorafenib, 
respectively, were quantified. The membranes were then stripped and reprobed with 
28
ht
tp
://
do
c.
re
ro
.c
h
antibodies against 4E-BP1 and Erk1/2 to measure total levels of each protein.  Actin was used 
as a loading control.  The immunoblots shown are representative of each group.  C. Effect of 
treatment on the phosphorylation of Akt (Ser473) in tumoral tissue. The phosphorylation 
of Akt (Ser473) was assessed by immunoblotting. The membrane was then stripped and 
reprobed with antibodies against Akt to measure the total level of the protein. Actin was used 
as a loading control. The immunoblots shown are representative of results from each group 
 
Fig. 6. Effect of everolimus and sorafenib on the vascular morphology and on the 
tumoral periphery.   A. Effect of sorafenib and combined sorafenib-everolimus on the 
vascular morphology of the tumors using the vascular casts technique. The SEM 
microphotograph shows a typical tumoral vascular pattern with abundant vascular sprouts 
(arrows) in the untreated (vehicle) tumor (left panel).  In the sorafenib-treated tumor (middle 
panel), the vascular sprouts are rare (arrows) whereas pillars (arrowheads) are a frequent 
finding. In the group treated with everolimus and sorafenib (right panel), vascular sprouts 
were absent and the larger sinusoidal vessels were pierced with numerous, irregularly 
positioned pillars (arrowheads).  Bars measure 20 μM for vehicle and sorafenib sections and 
ȝ0IRUHYHUROLPXVVRUDIHQLE  B. Histological analysis of the periphery of untreated and 
treated hepatic tumors. The periphery of untreated (drug vehicle) tumors was regular, 
encircled by a limiting capsule and showed no vascular invasion (left). Tumors treated with a 
combination of sorafenib and everolimus show an invasive front at the periphery, which 
extensively intercalates into the surrounding tissue (right). 
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